<DOC>
	<DOCNO>NCT00385658</DOCNO>
	<brief_summary>This study investigate effect combination fluvastatin fenofibrate dyslipidemia comparison combination simvastatin ezetimibe .</brief_summary>
	<brief_title>Efficacy Fluvastatin Fenofibrate Comparison Simvastatin Ezetimibe Patients With Metabolic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Fluvastatin</mesh_term>
	<criteria>Written inform consent participate study prior study procedure . Male female subject , age 1875 year inclusive . All woman child bear potential must negative pregnancy test Metabolic Syndrome accord International Diabetes Federation definition : Low plasma HDLC ( Men &lt; 40 mg/dl ; Women &lt; 50 mg/dl ) . Elevated waist circumference ( men ≥ 94 cm , woman ≥ 80cm ) And one follow criterion : Triglycerides ≥ 150 mg/d.l Raised blood pressure ( DBP ≥ 85 mmHg and/or SBP ≥ 130mmHg ) treat hypertension . Fasting plasma glucose≥ 100mg/dl . Previously diagnose type 2 diabetes . Dyslipidemia secondary cause nephrotic syndrome , autoimmune disease . Type 1 diabetes . HbA1c &gt; 9.5 % . Unexplained serum creatine phosphokinase &gt; 2 x Upper limit normal . History myocardial infarction and/or cerebral stroke and/or unstable angina pectoris . Known suspected contraindication warning accord country specific label investigational drug . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Dyslipidemia</keyword>
	<keyword>metabolic syndrome</keyword>
	<keyword>fluvastatin</keyword>
	<keyword>fenofibrate</keyword>
	<keyword>simvastatin</keyword>
	<keyword>ezetimibe</keyword>
</DOC>